Phase III PEG-Intron in HIV-infected Patients (Study P00738)

Summary

This is a randomized, double-blind, multicenter trial testing 2 doses of PEG-Intron, 1.0mcg/kg/week and 3.0mcg/kg/week in heavily treatment-experienced HIV-infected patients compared to placebo. The study will evaluate the efficacy and safety of PEG-Intron when added to stable optimized background antiretroviral therapy in this patient population.

Timeline

Start

2002-03

Primary completion

2003-10

Completion

2003-10

Drugs

Indications